申请人:VITAE PHARMACEUTICALS INC
公开号:WO2017024018A1
公开(公告)日:2017-02-09
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
提供了式I的新化合物:其药用盐以及药物组合物,可用于治疗由RORγ介导的疾病和紊乱。还提供了包含式I新化合物的药物组合物以及它们在治疗一种或多种炎症性、代谢性、自身免疫和其他疾病或紊乱中的使用方法。